New drug monitored for Tough-to-Treat virus in transplant patients
NCT ID NCT06577363
Summary
This study is monitoring the use of Maribavir tablets in Japan for patients who have received an organ or stem cell transplant and developed a Cytomegalovirus (CMV) infection that hasn't responded to other treatments. The main goals are to check how well the drug works to clear the virus and to track any side effects. Doctors will follow about 250 patients for 27 weeks as they take the medication according to standard medical practice.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS (CMV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Takeda selected site
RECRUITINGTokyo, Japan
Conditions
Explore the condition pages connected to this study.